Abstract:Purpose/Objective(s) Mucosal melanoma of the head and neck is a rare and deadly disease. The optimal treatment for mucosal melanoma remains uncertain, and there is no consensus on the most effective treatment approach, including the extent of surgical resection, the use of adjuvant therapy, and the role of immunotherapy. Current controversies and unknowns about disease treatment and outcomes stem from the rarity of mucosal melanoma, the lack of large-scale clinical trials, and the heterogeneity of the disease. This study aims to determine the survival benefit of immunotherapy, surgery and radiation in setting of mucosal melanoma. Materials/Methods We extracted data from NCDB database with histology codes (ICD-O 2 melanoma codes M872–M879) for patients with mucosal melanoma diagnosed from year 2000-2020 with a total sample size 3937. The patients’ characteristics were summarized by median and interquartile range (IQR) for a continuous variable and by frequency and percentage for a categorical variable. We considered the different combinations of treatments in terms of surgery, chemotherapy, radiation therapy, and immunotherapy. The outcome variables are (1) time to death since diagnosis, and (2) death. Kaplan-Meier survival estimates were used. The log-rank test was employed to compare the survival distributions of the different treatment groups. Cox Proportional Hazard Regression model was performed to evaluate the association between the treatment combinations and survival outcome, adjusting the clinical and demographic variables (e.g., sex, age, stage of cancer). Hazard ratio (HR) and 95% confidence interval (CI) were reported. Mortality rate for each treatment combination was also reported, and the multiple logistic regression model was used to examine the effect of different treatment on mortality. Results The median overall survival (OS) time for all patients diagnosed with mucosal melanoma was 25.7 months. Among them, 50.1% were males, 9.4% younger than 50 years old and 50.6% older than 70, 88.7% white, and 57.6% with Medicare. Cox proportional hazard model showed that the survival time is significantly associated with the following factors: age group 60-70 (HR 1.25, 95%CI [1.06, 1.48]) and >70 (HR 1.83, 95%CI [1.56, 2.13]) comparing with age group <50. Male sex increased the risk of death (HR 1.13, 95%CI[1.04, 1.22]). Surgery decreased the risk of death (HR 0.49, 95%CI [0.44, 0.55]). The use of radiation and immunotherapy had no association with survival. Chemotherapy increased the risk of death (HR 1.33, 95%CI [1.18,1.51]), and was associated with more advanced age and high tumor stage. The multiple logistic regression model showed similar impact of these factors on mortality. Conclusion Treatment paradigms for mucosal melanoma vary widely. Local therapy remains important for improved survival. Further analyses should be done to explore the benefits of multi-modality treatment.

Mohs Micrographic Surgery in the Surgical Treatment Paradigm of Melanoma In Situ and Invasive Melanoma: A Clinical Review of Treatment Efficacy and Ongoing Controversies

A review of Mohs micrographic surgery for skin cancer. Part 1: Melanoma and rare skin cancers

Mohs Micrographic Surgery for Invasive Melanoma Allows for Tissue Preservation Compared With Wide Local Excision: A Retrospective Cohort Study

Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta‐analyses

Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study

Mohs Micrographic Surgery: A Brief Overview

Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients.

Intraoperative Immunohistochemistry During Mohs Micrographic Surgery and Staged Excision Decreases Local Recurrence Rates for Invasive Cutaneous Melanoma: A Systematic Review and Meta-Analysis

Surgical Margins of Nonmelanoma Skin Cancers in Mohs Surgery: Dermoscopy Versus Naked Eye

Excision Margins for Melanoma in Situ on the Head and Neck – A Single-Center 10-year Retrospective Review of Treatment with Mohs Micrographic Surgery

Clinical Versus Histologic Margins for Cutaneous Squamous Cell Carcinoma: Comparing Outcomes for High-Risk Tumors Treated With Mohs Micrographic Surgery

Review on the Role of Paraffin-embedded Margin-controlled Mohs Micrographic Surgery to Treat Skin Tumors

Mohs micrographic surgery challenges and new technologies to optimize care of cutaneous malignancies of the ear

Treatment of sebaceous carcinoma with Mohs micrographic surgery versus wide local excision: a systematic review

Cutaneous mesenchymal tumors treated with Mohs micrographic surgery: a comprehensive review

micrographic surgery for invasive melanoma of the trunk and proximal portion of the extremities

Local Therapy in the Management of Mucosal Melanoma: An NCDB Analysis

A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management

Beyond the Scalpel: Advancing Strategic Approaches and Targeted Therapies in Nonexcisable Melanomas

Enhanced Disease-Specific Survival Among Individuals With Malignant Adnexal Tumors of the Skin Treated With Mohs Surgery: A National Database Study

Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review